Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

Anita H. Clayton; Sophie Ma; François Laliberté

doi:10.1080/13696998.2025.2587412

November 30, 2025Journal of Medical EconomicsOpen Access

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

View Full Paper

Ask AI

Bookmark

Share

Key Points

Earlier cariprazine use potentially lowers economic burden of major depressive disorder.
This study suggests a notable reduction in substantial humanistic and economic impact with timely intervention.
Observational analysis of Medicaid beneficiaries indicates a significant association between treatment timing and cost.
Implications suggest the need for re-evaluation of treatment strategies in managing major depressive disorder.

Implication

Real-world evidence shows earlier adjunctive therapy with cariprazine reduces economic burden in patients with major depressive disorder.

Abstract

Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Clayton et al. (2025) studied this question.

synapsesocial.com/papers/6930dc78ea1aef094cca219c https://doi.org/10.1080/13696998.2025.2587412

View Full Paper

Ask AI

Bookmark

Share

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

Key Points

Implication

Abstract

Discussion

Cite This Study

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading